Rituximab in primary podocytopathies: efficacy and safety in a retrospective cohort
In conclusion, our results suggest that RTX is a useful therapeutic option not only for steroid-sensitive podocytopathies, but also in selected steroid-resistant cases, determining a proteinuria decrease that can contribute positively to the clinical management of such glomerular diseases. RTX was generally efficient and well tolerated in this adult cohort.
Authors
- Gabriel Teixeira Montezuma Sales (ORCID: https://orcid.org/0000-0002-7618-2782)
- Danilo Euclides Fernandes (ORCID: https://orcid.org/0000-0002-6324-1763)
- Gianna Mastroianni Kirsztajn (ORCID: https://orcid.org/0000-0003-1317-4109)
Institutions
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Brazilian Journal of Nephrology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1590/2175-8239-jbn-2025-0120en
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00